Li Hong-Hua, Wu Xiao-Xiong, Wang Quan-Shun, Zhao Yu, Bo Jian, Wang Shu-Hong, DA Wan-Ming, Yu Li
Department of Hematology, General Hospital of PLA, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):298-300.
The study was aimed to evaluate the effect of IEMAD (modified MIME) composed of isofosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone, in treatment of refractory or relapsed non-Hodgkin's lymphoma. Twenty-five patients with refractory or relapsed non-Hodgkin's lymphoma (11 refractory NHL patients, 14 relapsed NHL patients) were treated with IEMAD regimen. The results showed that the complete remission rate was 24.0% (6/25) and the partial remission rate was 28.0%, having an overall response rate of 52%. The median survival duration was 13 months and the median duration of progression-free survival was 8 months. The most frequent complications were gastrointestinal complaint (nausea, vomiting etc.) and myelosuppression. No treatment related mortality was found. It is concluded that the IEMAD (modified MIME) regimen may be a safe and effective regimen that can be used in treatment of patients with refractory or relapsed non-Hodgkin's lymphoma who did not respond to other regimens.
本研究旨在评估由异环磷酰胺、威猛（VM26）或鬼臼乙叉苷（VP16）、甲氨蝶呤、阿糖胞苷、地塞米松或甲泼尼龙组成的IEMAD（改良MIME）方案治疗难治性或复发性非霍奇金淋巴瘤的疗效。25例难治性或复发性非霍奇金淋巴瘤患者（11例难治性非霍奇金淋巴瘤患者，14例复发性非霍奇金淋巴瘤患者）接受IEMAD方案治疗。结果显示，完全缓解率为24.0%（6/25），部分缓解率为28.0%，总缓解率为52%。中位生存期为13个月，无进展生存期的中位持续时间为8个月。最常见的并发症是胃肠道不适（恶心、呕吐等）和骨髓抑制。未发现与治疗相关的死亡病例。结论是，IEMAD（改良MIME）方案可能是一种安全有效的方案，可用于治疗对其他方案无反应的难治性或复发性非霍奇金淋巴瘤患者。
